BridgeBio Pharma shares are moving higher as the market focuses on near-term scientific catalysts in transthyretin amyloid cardiomyopathy (ATTR-CM), particularly upcoming long-term open-label extension (OLE) ATTRibute-CM data tied to Attruby (acoramidis) that is slated for presentation at ACC 2026. The stock’s gain appears consistent with pre-event positioning after the company highlighted that new OLE data and related real-world survey results would be featured in a late-breaking oral session and additional poster presentations at ACC.

Attruby is BridgeBio’s commercial anchor, and incremental datasets that reinforce durability, safety, and real-world effectiveness can influence prescriber confidence and support continued adoption. BridgeBio has recently emphasized Attruby’s differentiation narrative (including high TTR stabilization and early clinical-outcome separation) while also pointing to a growing prescription base and a broader buildout of commercial execution, keeping investor attention tightly linked to external clinical validation events like ACC.

Beyond ATTR-CM, BridgeBio has framed 2026 as a filing-heavy year, with planned first-half 2026 NDA submissions for BBP-418 (LGMD2I/R9) and encaleret (ADH1), and a second-half 2026 NDA target for infigratinib (achondroplasia). That cluster of potential regulatory milestones, combined with the company’s recent balance-sheet actions and revenue growth narrative tied to Attruby, has helped keep BBIO trading as a catalyst-driven large-cap biotech name.